The Value of 68Ga-FAPI PET/CT in Preoperative Evaluation of Thyroid Cancer with Lymph Node Metastases
- Conditions
- Thyroid Cancer
- Registration Number
- NCT06730529
- Lead Sponsor
- Ruijin Hospital
- Brief Summary
This study aims to investigate the value of 68Ga-FAPI in the preoperative evaluation of thyroid cancer of different pathologic types.
- Detailed Description
The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo a 68Ga-FAPI PET/CT before surgery. The imaging response measurements will be compared with the histopathological results as gold standard.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 40
- Pathological and clinical diagnosis of thyroid cancer with lymph node metastases.
- Signed and dated informed consent form.
- Commitment to comply with research procedures and co-operation in the implementation of the full research process.
- Aged 16-80 years old.
- Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
- Intestinal perforation, complete intestinal obstruction.
- Pregnant women and women who may be pregnant, women who are breastfeeding.
- Non-compliant person.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical staging of thyroid cancer with lymph node metastasis Within 1 week after enrollment The value of 68Ga-FAPI PET/CT in the evaluation of thyroid cancer with lymph node metastases in clinical staging
- Secondary Outcome Measures
Name Time Method Standardized uptake value(SUV) Within 1 week after enrollment SUV of 68Ga-FAPI uptake on PET/CT images for tumor lesions
Disease free survival 3 years Disease free survival
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
🇨🇳Shanghai, Shanghai, China